Drugging the Undruggable RAS in Pancreatic Cancer cover art

Drugging the Undruggable RAS in Pancreatic Cancer

Drugging the Undruggable RAS in Pancreatic Cancer

Listen for free

View show details

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

This summer, a new targeted treatment for pancreatic cancer was approved by the FDA. The treatment, Rasonque (daraxonrasib), is giving new hope to people with a disease that had been seen as almost untreatable. In this episode, Chuck and Alicia unpack this new development with Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, who led the drug trial.

No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.